These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 24668702)

  • 1. Comparison of effects of nebivolol, carvedilol and irbesartan on left ventricular hypertrophy associated with hypertension.
    Degirmenci H; Açikel M; Bakirci EM; Duman H; Demirelli S; Tas H; Simsek Z; Karakelleoglu S; Aksakal E; Erol MK
    Eur Rev Med Pharmacol Sci; 2014; 18(5):630-7. PubMed ID: 24668702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tissue velocity echocardiography shows early improvement in diastolic function with irbesartan and atenolol therapy in patients with hypertensive left ventricular hypertrophy. Results form the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA).
    Müller-Brunotte R; Kahan T; Malmqvist K; Ring M; Edner M
    Am J Hypertens; 2006 Sep; 19(9):927-36. PubMed ID: 16942935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aortic elastic properties : effects of carvedilol versus nebivolol.
    Sayin MR; Aydin M; Dogan SM; Karabag T; Cetiner MA; Aktop Z
    Herz; 2013 May; 38(3):299-305. PubMed ID: 23263241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymorphisms in the angiotensinogen and angiotensin II type 1 receptor gene are related to change in left ventricular mass during antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial.
    Kurland L; Melhus H; Karlsson J; Kahan T; Malmqvist K; Ohman P; Nyström F; Hägg A; Lind L
    J Hypertens; 2002 Apr; 20(4):657-63. PubMed ID: 11910301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of effect of irbesartan and nebivolol on the left atrium volume and deformation in the patients with mild-moderate hypertension.
    Degirmenci H; Duman H; Demirelli S; Bakirci EM; Hamur H; Inci S; Simsek Z; Askın L; Arısoy A; Lazoglu Z
    Eur Rev Med Pharmacol Sci; 2014; 18(6):781-9. PubMed ID: 24706300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of carvedilol and nebivolol on oxidative stress-related parameters and endothelial function in patients with essential hypertension.
    Zepeda RJ; Castillo R; Rodrigo R; Prieto JC; Aramburu I; Brugere S; Galdames K; Noriega V; Miranda HF
    Basic Clin Pharmacol Toxicol; 2012 Nov; 111(5):309-16. PubMed ID: 22703478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Three-dimensional echocardiographic and magnetic resonance assessment of the effect of telmisartan compared with carvedilol on left ventricular mass a multicenter, randomized, longitudinal study.
    Galzerano D; Tammaro P; del Viscovo L; Lama D; Galzerano A; Breglio R; Tuccillo B; Paolisso G; Capogrosso P
    Am J Hypertens; 2005 Dec; 18(12 Pt 1):1563-9. PubMed ID: 16364826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of carvedilol on coronary flow reserve in patients with hypertensive left-ventricular hypertrophy.
    Xiaozhen H; Yun Z; Mei Z; Yu S
    Blood Press; 2010 Feb; 19(1):40-7. PubMed ID: 20001392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison between nebivolol and ramipril in patients with hypertension and left ventricular hypertrophy: a randomized open blinded end-point (PROBE) trial.
    Cağlar N; Dincer I
    Eur Rev Med Pharmacol Sci; 2011 Dec; 15(12):1359-68. PubMed ID: 22288296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transforming growth factor beta1 genotype and change in left ventricular mass during antihypertensive treatment--results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA).
    Hallberg P; Lind L; Billberger K; Michaelsson K; Karlsson J; Kurland L; Kahan T; Malmqvist K; Ohman KP; Nyström F; Liljedahl U; Syvänen AC; Melhus H
    Clin Cardiol; 2004 Mar; 27(3):169-73. PubMed ID: 15049387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of nebivolol versus carvedilol on left ventricular function in patients with chronic heart failure and reduced left ventricular systolic function.
    Lombardo RM; Reina C; Abrignani MG; Rizzo PA; Braschi A; De Castro S
    Am J Cardiovasc Drugs; 2006; 6(4):259-63. PubMed ID: 16913827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of irbesartan versus atenolol on left ventricular mass and voltage: results of the CardioVascular Irbesartan Project.
    Schneider MP; Klingbeil AU; Delles C; Ludwig M; Kolloch RE; Krekler M; Stumpe KO; Schmieder RE
    Hypertension; 2004 Jul; 44(1):61-6. PubMed ID: 15184349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of irbesartan vs felodipine in the regression after 1 year of left ventricular hypertrophy in hypertensive patients (the SILVER trial). Study of Irbesartan in Left VEntricular hypertrophy Regression.
    Cohen A; Bregman B; Agabiti Rosei E; Williams B; Dubourg O; Clairefond P; Brudi P; Gosse P; Guéret P
    J Hum Hypertens; 1998 Jul; 12(7):479-83. PubMed ID: 9702935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carvedilol and nebivolol improve left ventricular systolic functions in patients with non-ischemic heart failure.
    Karabacak M; Doğan A; Tayyar Ş; Özaydın M; Erdoğan D
    Anatol J Cardiol; 2015 Apr; 15(4):271-6. PubMed ID: 25413223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of antihypertensive treatment on the doppler-derived myocardial performance index in patients with hypertensive left ventricular hypertrophy: results from the Swedish irbesartan in left ventricular hypertrophy investigation versus atenolol (SILVHIA).
    Liljedahl S; Kahan T; Lind L; Arnlöv J
    Echocardiography; 2009 Aug; 26(7):753-8. PubMed ID: 19486119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effects of nebivolol and carvedilol on left ventricular diastolic function in older heart failure patients with preserved ejection fraction: study protocol for a randomized controlled trial.
    Park K; Park TH
    Trials; 2016 Nov; 17(1):530. PubMed ID: 27809882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of actions of irbesartan versus atenolol on cardiac repolarization in hypertensive left ventricular hypertrophy: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation Versus Atenolol (SILVHIA).
    Malmqvist K; Kahan T; Edner M; Bergfeldt L
    Am J Cardiol; 2002 Nov; 90(10):1107-12. PubMed ID: 12423712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative long term effects of nebivolol and carvedilol in hypertensive heart failure patients.
    Marazzi G; Volterrani M; Caminiti G; Iaia L; Massaro R; Vitale C; Sposato B; Mercuro G; Rosano G
    J Card Fail; 2011 Sep; 17(9):703-9. PubMed ID: 21872138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. B2 bradykinin receptor (B2BKR) polymorphism and change in left ventricular mass in response to antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial.
    Hallberg P; Lind L; Michaëlsson K; Karlsson J; Kurland L; Kahan T; Malmqvist K; Ohman KP; Nyström F; Melhus H
    J Hypertens; 2003 Mar; 21(3):621-4. PubMed ID: 12640257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myocardial fibrosis and diastolic dysfunction in patients with hypertension: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA).
    Müller-Brunotte R; Kahan T; López B; Edner M; González A; Díez J; Malmqvist K
    J Hypertens; 2007 Sep; 25(9):1958-66. PubMed ID: 17762662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.